licensing

Drug Registration in Indonesia: BPOM Approval and NIE

Drug registration in Indonesia: who holds the BPOM marketing authorisation (NIE), review times, renewal, import approvals and the supplement route.

Jurisdiction
Indonesia
Last reviewed
3 Nov 2026
References (8)
  • Perka BPOM No. 24 Tahun 2017 on drug registration, as amended by Peraturan BPOM No. 15 Tahun 2019, 27 Tahun 2020, 13 Tahun 2021, 15 Tahun 2023 and 23 Tahun 2025. Articles 1 points 14 and 47 (the registrant; working days, as rewritten in 2025), 2 (every drug needs a marketing authorisation), 8(1) (local manufacture), 9(1) and 18 (contract and licensed manufacture), 11(2) and 15 (imported drugs), 25, 26, 27(2), 33, 34 and 36 (stages, fee, dossier, pre-registration), 31 (patient information), 37(1) (evaluation lanes, as rewritten in 2025), 42 (renewal), 48 (data requests), 51 (approval, as amended in 2019), 58 and 59 (validity).
  • Peraturan BPOM No. 23 Tahun 2025, the fifth amendment to Perka BPOM 24/2017, promulgated 12 August 2025. Annex II (minimum label content) and Article II point 1 (labels approved earlier comply within 24 months).
  • Peraturan BPOM No. 33 Tahun 2025 on good manufacturing practice assessment of overseas sites for imported drugs. Articles 2(2) and 3.
  • Peraturan BPOM No. 27 Tahun 2025 on business-licensing standards. Annex A.1 point 5.3 (make or import within a year).
  • Peraturan BPOM No. 32 Tahun 2022 on health supplement registration, as amended by Peraturan BPOM No. 15 Tahun 2024. Articles 20, 35(2), 36(1)(b), 40(1), 42, 74(3) and 91.
  • Peraturan BPOM No. 25 Tahun 2023 on traditional medicine (obat bahan alam) registration. Articles 18, 33(2), 34(1)(b), 37(1), 38, 72(3) and 87.
  • Peraturan BPOM No. 27 Tahun 2022 on the import of drugs and food, as amended by Peraturan BPOM No. 28 Tahun 2023. Articles 1 point 7, 3 and 4(1).
  • Peraturan BPOM No. 10 Tahun 2024 on labelling of traditional medicine, quasi-drugs and supplements. Article 8(1).

Drug registration in Indonesia is how BPOM (Badan Pengawas Obat dan Makanan, the food and drug authority) grants a drug its marketing authorisation, the izin edar, whose number (the NIE, Nomor Izin Edar) appears on the label. Every drug sold in Indonesia needs one, and the registrant applies to the head of BPOM (BPOM Regulation 24 of 2017, Article 2).

Under that regulation the registrant is a licensed pharmaceutical manufacturer. The registration (registrasi obat) has two stages, pre-registration and registration, and the authorisation lasts up to 5 years (Articles 25(1) and 58(1)). Health supplements and traditional medicine follow their own BPOM rules, covered further down.

Who can register a drug

The registrant must be a pharmaceutical manufacturer (Industri Farmasi) holding a pharmaceutical industry licence (Article 1 point 14, as rewritten by BPOM Regulation 23 of 2025). For a drug made in Indonesia, the manufacturer also needs a valid good manufacturing practice certificate (CPOB, Cara Pembuatan Obat yang Baik) for the dosage form it registers (Article 8(1)).

The same holds for a drug made under licence or on contract: the licensee, or the company that gives the contract, registers it (Articles 9(1) and 18). Supplements and traditional medicine differ, as the table shows, and are covered below.

Who registers what with BPOM
DrugSupplementTraditional
Who registers Licensed drug maker (BPOM Regulation 24/2017)Maker, importer or marketerMaker, importer or marketer
Imports Licensed maker; overseas maker’s approval unless an affiliateImporter, with an agency letter of 3 years or moreImporter, as for supplements
Review Lanes up to 300 working daysImported: up to 50 working daysImported: up to 90 working days
Validity Up to 5 yearsUp to 5 yearsUp to 5 years

Imported drugs

An imported drug is registered by a licensed pharmaceutical manufacturer with the overseas manufacturer’s written approval, which states how long the cooperation runs. A registrant that is an affiliate of the parent company needs no such approval (BPOM Regulation 24 of 2017, Article 15(1) to (3)). Priority goes to national health programme drugs, new discoveries and drugs needed but not made in Indonesia (Article 11(2)).

The overseas manufacturer must hold its home-country licence and meet good manufacturing practice, shown by documents (Article 15(4)). BPOM assesses the overseas site as part of the approval itself, by document review, a desktop inspection or a site inspection (BPOM Regulation 33 of 2025, Articles 2(2) and 3).

The registration follows the appointment

Agree the appointment for the full five years at the start. Where the overseas manufacturer appoints the registrant for a shorter term, the registration runs only that long. It is cancelled if the appointment ends early (BPOM Regulation 24 of 2017, Articles 58(3) and 59).

How drug registration in Indonesia works

Pre-registration settles the registration category, the evaluation lane, the fee and the documents needed. Its result issues within 40 working days and binds for 1 year (Articles 33 and 36). A locally made generic, a renewal and some variations skip this step (Article 34).

  1. 40 working days

    Pre-registration

    BPOM sets the category, lane, fee and documents.

  2. Pay within 10 working days

    Fee and dossier

    The registrant pays the fee and files the dossier.

  3. Lanes up to 300 working days

    Evaluation

    BPOM reviews the dossier in the set lane.

  4. Up to 5 years

    Approval

    Make or import the drug within a year.

  5. From 12 months before

    Renewal

    Renew before the five years run out.

The registrant pays the fee within 10 working days of BPOM’s payment order (Article 26(2)). The dossier follows the Common Technical Dossier of ASEAN (the Association of Southeast Asian Nations), in Indonesian or English (Articles 25(5) and 27(2)). While the registrant answers a request for more data, BPOM’s clock stops (Article 48).

BPOM issues the authorisation once commercial-scale production meets the requirements; before that, it can issue an approvable letter (Article 51, as amended by BPOM Regulation 15 of 2019).

How long BPOM’s review takes

BPOM sets an evaluation lane for each application: the time its review needs, counted in working days (Article 1 points 45 and 47 and Article 37(1), as rewritten by BPOM Regulation 23 of 2025). An ordinary generic has a lane of 150 working days, and a new drug or biologic one of 300 working days. A new drug already approved in at least one country with a well-known evaluation system has a lane of 90 working days. Shorter lanes exist for life-saving and orphan drugs, national health programme drugs and manufacturers investing in Indonesia (Article 37(1)(f), (g) and (i)).

BPOM’s review lanes for drugs, in working days
  • Renewal 10
  • New drug approved in a reference country 90
  • Generic or branded generic 150
  • New drug or biologic 300

BPOM Regulation 24 of 2017, Article 37(1), as rewritten by BPOM Regulation 23 of 2025

Keeping the registration

A drug registration in Indonesia lasts up to 5 years while the drug continues to meet the rules (Article 58(1)). The drug must be made or imported within a year of approval (BPOM Regulation 27 of 2025, Annex A.1 point 5.3).

Article 42(1) sets the renewal window at between 12 months and 2 months before expiry, with a later deadline for a renewal without changes (Article 42(2)). A renewal has a lane of 10 working days (Article 37(1)(c)). A renewal filed too late is treated as a new registration (Article 42(6)).

Patient information must be in Indonesian, and English may be added (Article 31).

Labels approved before BPOM Regulation 23 of 2025 must meet the new minimum label content in its Annex II, which replaces Annex XI, by 12 August 2027 (Article II point 1).

Each shipment needs an import approval

A shipment of imported drugs, health supplements or traditional medicine needs BPOM’s SKI (Surat Keterangan Impor) Border, held when the import declaration is filed. Narcotics, psychotropics and precursors have their own import approval instead. Each SKI covers one shipment (BPOM Regulation 27 of 2022, Article 3, as amended by BPOM Regulation 28 of 2023). The registration holder applies, or an importer it authorises (Article 1 point 7).

The product needs at least two-thirds of its shelf life left when the SKI is applied for, or nine months for a biologic (Article 4(1)). Cosmetics use the same SKI Border, with their own shelf-life rule, set out in cosmetics registration in Indonesia; processed food follows a post-border version, covered in food and beverage registration. Who may import at all is in importing goods into Indonesia.

Health supplements and traditional medicine

Traditional medicine (obat bahan alam) includes jamu, standardised herbal medicine and phytopharmaceuticals (Regulation 25 of 2023, Article 1). An imported health supplement or traditional medicine is registered by the Indonesian importer (BPOM Regulation 32 of 2022, Articles 20 and 35(2); BPOM Regulation 25 of 2023, Articles 18 and 33(2)). The importer holds an NIB (Nomor Induk Berusaha, the business identification number).

The importer holds a letter from the overseas producer or principal appointing it as agent with the right to register, valid for at least 3 years at registration. Each product from one overseas maker goes to one importer only (Regulation 32 of 2022, Articles 36(1)(b) and 42; Regulation 25 of 2023, Articles 34(1)(b) and 38). The importer also needs BPOM’s recommendation on its distribution facility and a responsible pharmacist (Regulation 32 of 2022, Article 40(1); Regulation 25 of 2023, Article 37(1)).

BPOM reviews a new imported supplement in up to 50 working days (Regulation 32 of 2022, Article 74(3)). It reviews an imported traditional medicine in up to 90 working days (Regulation 25 of 2023, Article 72(3)). Either registration lasts up to 5 years, or as long as the agency letter if that is shorter, and is renewed before it expires (Regulation 32 of 2022, Article 91; Regulation 25 of 2023, Article 87). Supplement labels are written in Indonesian, apart from the product name (BPOM Regulation 10 of 2024, Article 8(1)).

How MAM helps

Under BPOM’s drug registration regulation, the registrant is a licensed pharmaceutical manufacturer. MAM takes care of the registration process for the licensed manufacturer that holds it.

For health supplements and traditional medicine, an importer can register. MAM can set up the importing company as a foreign-owned company (PT PMA), and takes care of the registration once the importing company is in place.

Bringing medicines to Indonesia?

Tell us the product and where it is made. We will explain who must hold the authorisation and take care of the BPOM filing.

Related services

Where this applies

Foreign Company (PT PMA)

A PT PMA is the foreign-investment company: up to 100% foreign ownership, subject to your KBLI.

Local Company (PT PMDN)

A local Indonesian company (PT PMDN) is the domestic entity: Indonesian shareholders, and no legal minimum capital.

WhatsApp